Optimized construction of MUC1-VNTR<sub>n</sub> DNA vaccine and its anti-pancreatic cancer efficacy

YUAN-FENG GONG<sup>1*</sup>, QUAN-BO ZHOU<sup>2*</sup>, YA-DI LIAO<sup>1</sup>, CONG MAI<sup>1</sup>, TIE-JUN CHEN<sup>1</sup>, YUN-QIANG TANG<sup>1</sup> and RU-FU CHEN<sup>2</sup>

<sup>1</sup>Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510095;  <sup>2</sup>Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China

Received September 1, 2015; Accepted November 3, 2016

DOI: 10.3892/ol.2017.5717

Abstract. Considering mucin 1-variable number tandem repeat (MUC1-VNTR<sub>n</sub>) as a novel target for pancreatic cancer immunotherapy, the present study aimed to screen and identify the pVAX1-MUC1-VNTR<sub>n</sub> DNA vaccine with the strongest immunogenicity. Following construction of a pVAX1-MUC1-VNTR<sub>n</sub> plasmid, immature dendritic cells (DCs) were subjected to transfection, and mature DCs were then co-cultured with autologous T-cells. The numbers of cytotoxic T lymphocytes (CTLs) secreting interferon (IFN)-γ were determined using an enzyme-linked immunospot assay, and Cytotoxic<sup>®</sup> was also used to examine the MUC1-VNTR<sub>n</sub>-specific Lethal effect of CTLs on Capan2 cells. Additional in vivo experiments in mice were performed to confirm the antitumor effect of the DNA vaccine candidate. The present study successfully constructed the pVAX1-MUC1-VNTR<sub>n</sub> plasmid, which expresses the target protein in eukaryotic cells, and pVAX1-MUC1-VNTR<sub>n</sub> has the potential to express the target protein in eukaryotic cells, and thatpVAX1-MUC1-VNTR<sub>n</sub> was characterized by the strongest Lethal effect in both in vivo and in vitro experiments.

Introduction

Pancreatic cancer is an aggressive solid malignancy that occurs in the pancreas with clinical symptoms such as abdominal pain, back pain, sallow skin, unexplained weight loss and anorexia (1). In the United States, pancreatic cancer is the most common type of digestive cancer with an incidence of ~44,000 patients diagnosed per year, second only to colorectal cancer (2). With a morbidity rate of 2.8% in male and 3.2% in female patients, pancreatic cancer is the fifth leading cause of cancer-associated mortality in Europe; it is responsible for an estimated 70,000 mortalities annually in the Western world (3). The specific mechanisms underlying the initiation, development and maintenance of pancreatic cancer remain largely unknown, although it is considered that a variety of factors, such as tobacco, alcohol, coffee, diabetes and chronic pancreatitis, and even blood type, may contribute to the pathology of pancreatic cancer (2,4). Pancreatic cancer can also result from overexpression of onco genes, inactivation of tumor suppressor genes or dysregulation of various signaling proteins (5). Current available treatments for pancreatic cancer are relatively inefficacious, and tumor resection surgery is the only choice that enables the possibility of long-term
survival (6,7). The high 5-year mortality of pancreatic cancer is a combined consequence of delayed and inaccurate diagnostic techniques, and limited treatment options (4,8). All these clinical difficulties lead to an urgent requirement for an effective and accurate therapeutic tool for pancreatic cancer prevention and treatment.

Several previous studies have shown that mucin 1 (MUC1), a type of epithelial protein, is expressed in numerous malignant hemato poetic cell lines and is overexpressed in malignant tumor tissues, thus being implicated as a potential biomarker for cancers (9,10). Notably, the expression of MUC1 was observed in almost all examined pancreatic cancer cells, which suggests that MUC1 plays an instrumental role in the progression of pancreatic cancer. MUC1 represents a unique type of target that shows better efficacy when combined with immunotherapy rather than radiotherapies or chemotherapies; importantly, it allows specific targeting of the tumor without eliciting damage to adjacent normal tissues (11,12). Variable number of tandem repeat (VNTR) is defined as a variable number of connected repeats of a 20-amino acid sequence in the extracellular domain of MUC1. In normal cells, it is heavily glycosylated at the threonine and serine residues; however, it has underglycosylated VNTR domains that are overexpressed in 90% of pancreatic cancer (13). Previous studies have indicated that MUC1 exhibits abnormally high expression and incomplete glycosylation in pancreatic cancer epithelial cells, with exposed extracellular VNTRs that potentially become a new target for pancreatic cancer immunotherapy (14,15). DNA vaccines are a rapidly deployed next generation vaccination system that mainly contributes to the treatment of human and animal diseases by encoding antigenic proteins that initiate and mediate antibody- and cell-mediated immune responses (16). Increasing evidence suggests that the DNA vaccines of MUC1-VNTR may influence cancer prognosis and treatment, although no previous studies have clarified the precise number of the repeat sequences of MUC1-VNTR, that allows for the optimum immunogenicity (17,18). Therefore, the current study aimed to screen for and identify the MUC1-VNTR DNA vaccine with the strongest immunogenicity by constructing different extracellular repeats and assessing their effects in vitro and in vivo.

Materials and methods

Ethical issues. The present study was approved by the Animal Ethics Committee of the Affiliated Cancer Hospital of Guangzhou Medical University (Guangzhou, China). All experiments were conducted in strict accordance with the established Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.

Cell lines. The human pancreatic cancer cell strain Capan2 (MUC1-positive), mouse pancreatic cancer cell strain panc02 (MUC1-negative) and cervical carcinoma cell strain HeLa (MUC1-negative) were obtained from the laboratory center of the Affiliated Cancer Hospital of Guangzhou Medical University. The cells were cultured in an atmosphere containing 5% CO₂ at 37°C. Cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (both Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Construction of the stable panc02-MUC1 cell line expression MUC1 was completed by Ryder Company (Guangzhou, China).

Construction of pVAX1-MUC1-VNTRₙ plasmid. The MUC1-VNTRₙ gene (one repeat of VNTR encoded 20 amino acids GVTSA PDPTRPAGSTAPPAH) (19) was synthesized and provided by Takara Biotechnology Co., Ltd. (Dalian, China). Two single repeat amino acid sequences of PDTP were added close to the C-terminus (strong immunogenicity, strong MUC1-VNTRₙ) or N-terminus (weak immunogenicity, weak MUC1-VNTRₙ) of MUC1-VNTRₙ (Table 1). The MUC1-VNTRₙ target gene sequence was obtained after n repeats of strong MUC1-VNTRₙ, and then cloned into pVAX1 (Invitrogen; Thermo Fisher Scientific, Inc.). The MUC1-VNTRₙ plasmid and pVAX1 vector were subjected to double enzyme digestion (Hind and KpnI) at 37°C for 2 h. The products of digestion were isolated by 1% agarose gel electrophoresis and verified using the UV imaging system. Subsequently, the ligation reaction was prepared in a 10 µl volume containing: 3 µl VNTR gene, 2 µl pVAX1 vector, 1 µl 10X ligase buffer (Takara Biotechnology Co., Ltd.), 1 µl T4DNA ligase and 3 µl distilled H₂O. This reaction was incubated at 16°C for 2 h. The ligation reaction product was subsequently transformed into Escherichia coli DH5α competent cells. The cells were cultured on Luria-Bertani agar medium containing 50 µg/ml kanamycin (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) to discriminate between recombinant and non-recombinant cells. The plates were incubated at 37°C for 16 h. The recombinant plasmids were digested using a double enzyme digest. The digested product was isolated by 1% agarose gel electrophoresis, and then sent for sequencing (Takara Biotechnology Co., Ltd.). The result was compared with the target sequence using BLAST. The HeLa cell strain (MUC1-negative) was transfected with pVAX1-MUC1-VNTRₙ. The blank pVAX1 was used as control group. At 48 h following transfection (X-tremeGENE HP DNA Transfection Reagent; Roche Diagnostics, Basel, Switzerland), expression of the target protein MUC1-VNTRₙ was examined using western blot analysis. Total protein was isolated from the HeLa cells using a radioimmunoprecipitation assay protein lysis buffer (Biyuntian, Shanghai, China). The concentration of protein was determined using a BCA protein quantification kit (Biyuntian), according to the manufacturer's protocol. A total of 20 µg protein was separated using a 12% (w/v) sodium dodecyl sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE) according to the standard protocol, and then transferred to a polyvinylidene difluoride membrane. The membrane was incubated with the anti-MUC1-VNTR monoclonal antibody (cat. no. VU4HS; Cell Signaling Technology, Inc., Danvers, MA, USA; 1:1,000) at 4°C overnight. The membrane was subsequently incubated with the secondary goat anti-mouse immunoglobulin G antibody (Boster, China; 1:5,000) at room temperature for 1 h. Subsequently, the experiment results were obtained and analyzed by coloration using the SuperSignal West Pico kit (Thermo fisher Scientific, Inc.), development and fixing of the photographic materials.

Dendritic cell (DC) culture and biological characteristics. Peripheral blood leukocyte suspensions from healthy subjects
were collected from the Guangzhou Blood Bank (Guangzhou, China). Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll density gradient centrifugation. PBMCs were adjusted to 5x10^6/ml in RPMI-1640 culture medium containing 10% fetal bovine serum (both Gibco; Thermo Fisher Scientific, Inc.), 2 mmol/L-glutamine and 100 U/ml penicillin-streptomycin, and then incubated at 37°C in 5% CO_2 for 2 h to remove non-adherent cells. Adherent cells were cultured in RPMI-1640 culture medium supplemented with 1,000 U/ml granulocyte macrophage colony-stimulating factor (GM-CSF) and 500 U/ml interleukin (IL)-4, and approximately half of the medium was changed to supplement cell factors every other day. Immature DCs were obtained on the 6th day (control group) and divided into four groups: Group A, in which immature DCs were cultured with GM-CSF and IL-4; group B, in which immature DCs were treated with 1,000 U/ml tumor necrosis factor-α (TNF-α); group C, in which immature DCs were transfected with the VNTR_1 plasmid; and group D, in which immature DCs were transfected with the VNTR_1 plasmid and treated with 1,000 U/ml TNF-α. At 24 h following induction with TNF-α and plasmid, mature DCs were obtained, and the surface markers, cluster of differentiation CD80, CD86 and human leukocyte antigen-antigen D related (HLA-DR), were analyzed using flow cytometry (Cytomics FC 500MPL) performed by the Flow Cytometry Department of the Sun Yat-Sen Memorial Hospital Laboratory Center (Guangzhou, China). Additionally, the supernatant of DCs was collected to quantify the levels of IL-12, IL-4, IL-17, IL-10 and interferon (IFN)-γ using an ELISA kit (Neobioscience, Shenzhen, China).

**Detection of CTLs producing IFN-γ using the enzyme-linked immunospot (ELISPOT) assay.** The concentrations of DCs loaded with different MUC1-VNTR_n antigens (MUC1-VNTR_n antigens, n=3, 4, 6 and 9) in these four groups were adjusted to 1x10^5/ml. Autologous T-cells from the peripheral blood suspensions were filtrated using nylon wool columns were used as effector cells, and were adjusted to 1x10^6/ml. A total of 100 µl of DCs and T-cells were added to the ELISPOT plate (BD Biosciences, Franklin Lakes, NJ, USA) in the ratio of 1:10. Subsequently, 100 µl culture medium was added to one group of effector cells (3 wells), while 100 µl culture medium containing 2 µg/ml phytohemagglutinin was added to another group of effector cells (3 wells). Cells were then incubated at 37°C with 5% CO_2 for 16 h. The IFN-γ ELISPOT kit (BD Biosciences) was used to detect IFN-γ-producing CTLs according to the manufacturer's protocol. The organization of the groups is presented in Table II.

**Lethal effect of CTLs in vitro.** Mature DCs loaded with different MUC1-VNTR_n antigens and autologous T-cells (ratio 1:10) were seeded into a 6-well plate supplemented with 100 U/ml IL-2 culture medium; approximately half of the medium was changed to supplement cell factors every other day. Subsequent to a 5-day culture, the cells were counted using a light microscope. A total of three groups were classified: MUC1-VNTR_n group; pVAX1 without vector group; and HeLa cells group (negative control group). The organization of the groups is presented in Table II. MUC1-positive Capan2

| MUC1-VNTR | Strong target gene | Weak target gene |
|-----------|------------------|-----------------|
| VNTR_1    | GCTAGCGCCACCATG  | GCCACC          |

The strong target gene shows strong immunogenicity, as the PDTRP sequence has been added to the C-terminal end of MUC1-VNTR. The weak target gene shows weak immunogenicity, as the PDTRP sequence has been added to the N-terminal end of MUC1-VNTR. GCCACC is a Kozak sequence and the italic part refers to MUC1-VNTR_1. MUC1, mucin 1; VNTR, variable number of tandem repeats.
cell strains were collected as the target cells, and the effector cells and target cells were seeded into a 96-well plate with the ratio of 40:1. The Lethal effect of CTLs was examined using the CytoTox Non-Radioactive Cytotoxicity assay kit (Promega Corporation, Madison, WI, USA), according to the manufacturer’s protocol.

Establishment of pancreatic cancer in mice. A total of 120 female C57BL/6 mice were purchased from the laboratory animal center of Sun Yat-Sen University (Guangzhou, China). The experiments were performed in strict accordance with the requirements of biosafety rules and operated under the protocol of the laboratory animal center of Sun Yat-Sen University. The C57BL/6 mice were housed at a controlled temperature of between 20 and 26°C with a relative humidity of between 40 and 60%. The mice were subjected to a 12 h light-dark cycle and were fed and given water 2 times/week. The C57BL/6 mice were randomly divided into eight groups (n=10 per group): i) Empty vector group; ii) panc02 control group; iii) strong VNTR group; iv) weak VNTR group; v) VNTR group; vi) VNTR group; vii) VNTR group; and viii) VNTR group. The organization of the groups is presented in Table II. The mice in each group were injected into the right anterior tibial muscle with 100 µg/100 µl plasmid DNA in PBS3 times at 2-week intervals. At 1 week following the third injection, the C57BL/6 mice were treated with subcutaneous injection of 5x10⁶/100 µl panc02-MUC1 or panc02 cells into the left leg. The tumor size (long and short diameter) was measured every 2–3 days for 4 weeks, and the survival time was recorded.

Treatment of tumor-bearing mice. The second batch of 60 C57BL/6 mice were randomly divided into the same eight groups (n=10 per group). The mice were subcutaneously injected with 5x10⁷/100 µl panc02 or panc02-MUC1 cells. On the 4, 8 and 12th days following inoculation of the tumor cells, the mice were administered intramuscular injection of 100 µg/100 µl plasmid in PBS solution. Additionally, the tumor size (long/short diameter) was measured every 2–3 days for 4 weeks to generate the tumor growth curve. The survival time was recorded.

Statistical analyses. Measurement data are expressed as the mean ± standard deviation. The comparison between two independent samples was performed using Student’s t-test. Additionally, measurement data were compared using analysis of variance, and the Fisher’s least significant difference (LSD) test was applied for comparisons among multiple groups. SPSS 16.0 statistical software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. P<0.05 was considered to indicate a statistically significant difference.

Results

Plasmid construction. The present study successfully constructed 7 plasmids containing weak pVAX1-MUC1-VNTR, strong VNTR, VNTR, VNTR, VNTR, VNTR, and pVAX1-MUC1 (empty plasmid). Double digestion products of the plasmids were separated by agarose gel electrophoresis, and the present study was able to confirm the insertion of the target gene fragments.
2202

The supernatants of immature DCs and cytokine/antigen-induced mature DCs were collected to determine the amounts of secreted IL-12, IL-10, IL-4, IL-17 and IFN-γ using double-antibody sandwich ELISAs, which indirectly reflected the degree of maturation in DCs. As shown in Table IV, there were no significant differences in the levels of IL-12, IL-10, IL-4, IL-17 and IFN-γ between days 6 and 7 without stimulation (all P>0.05). Additionally, no significant differences were found in the levels of IL-12, IL-10, IL-4, IL-17 and IFN-γ between the supernatants of TNF-α-induced, VNTR1 plasmid-stimulated, and TNF-α+VNTR1 plasmid-stimulated groups (all P>0.05), while the pairwise comparisons using the LSD test showed significant differences between the stimulated and non-stimulated groups (all P<0.01).

Cultivation and biological characteristics of DCs. Under an inverted microscope (Fig. 1), mature DCs in suspension were found to be larger compared with leukomonocytes, with a spinous shape and numerous slender protrusions. As shown in Table III, expression of the surface markers CD80, CD86, and HLA-DR in mature DCs, as examined by flow cytometry, exhibited significant differences between the stimulated groups (groups B, C and D) and the control (all P<0.05). However, there was no significant difference among the DC phenotypes without stimulation on days 6 and 7 (P>0.05). Similarly, no significant differences were identified among the mature DC phenotypes subsequent to induction of the stimulated groups (all P>0.05). However, the pairwise comparisons between stimulated and non-stimulated groups showed significant differences (all P<0.05).

Table III. Dendritic cell phenotype, as determined by flow cytometry.

| Treatment group                      | CD80 (P-value) | CD86 (P-value) | HLA-DR (P-value) |
|--------------------------------------|----------------|----------------|------------------|
| Day 6 without stimulation (control group) | 10.12±4.15 (reference) | 19.25±8.76 (reference) | 70.89±8.21 (reference) |
| Day 7 without stimulation (group A)  | 16.86±8.05 (P=0.267) | 24.85±11.64 (P=0.542) | 71.62±8.31 (P=0.919) |
| TNF-α-stimulated maturation (group B) | 49.92±9.36 (P=0.003) | 89.68±2.12 (P<0.001) | 89.45±2.81 (P=0.021) |
| Stimulation by the VNTR1 plasmid (group C) | 53.87±8.41 (P=0.001) | 91.29±3.93 (P<0.001) | 90.83±4.91 (P=0.023) |
| TNF-α and VNTR1 plasmid co-stimulation (group D) | 58.63±9.05 (P=0.001) | 92.24±3.27 (P<0.001) | 93.43±3.62 (P=0.012) |

CD, cluster of differentiation; HLA-DR, human leukocyte antigen-antigen D related; TNF-α, tumor necrosis factor-α.

Figure 1. Mature dendritic cells in suspension under an inverted microscope at (A) magnification, x20 and (B) magnification, x40, were larger compared with leukomonocytes, with spinous processes and a number of slender protrusions, as indicated by the black arrow.
pVAX1-MUC1-VNTRn enhances the cytotoxicity of CTLs. As shown in Fig. 3, a stronger Lethal effect on Capan2 cells was observed for the T-cells stimulated with VNTRn and VNTRnDCs compared with the other groups (VNTRn, weak VNTRn, VNTRn, and MUC1-cDNA). *P<0.001. VNTR, variable number tandem repeat; MUC1, mucin 1.

pVAX1-MUC1-VNTRn DNA vaccine suppresses panc02-MUC1 tumor growth in vivo. Compared with the empty vector and panc02 control groups, the strong pVAX1-MUC1-VNTRn,
VNTR₁, VNTR₃, VNTR₅, and VNTR₉ groups showed significantly increased inhibitory effects on pANC02-MUC1 cell tumor growth from day 12 following tumor challenge (all P<0.001; Fig. 4). In addition, the inhibitory effect of the weak VNTR₁ DNA plasmid on pANC02-MUC1 tumor growth was significantly milder compared with the other pVAX1-MUC1-VNTR DNA vaccines (all P<0.05). LSD analysis indicated that the pVAX1-MUC1-VNTR DNA vaccine showed a stronger suppressive effect on pANC02-MUC1 tumor growth compared with the strong pVAX1-MUC1-VNTR1, VNTR3, VNTR4, VNTR5, and VNTR9 vaccines (all P<0.01), while there was no significant difference among the strong pVAX1-MUC1-VNTR1, VNTR3, VNTR4, and VNTR9 groups (all P>0.05; Fig. 5). No evident inhibitory effects on pANC02 tumor cells were found for all pVAX1-MUC1-VNTR DNA vaccines (Fig. 5), indicating strong MUC1 specificity.

**Discussion**

The present study, utilizing MUC1-VNTR₉ as a potentially novel target for pancreatic cancer immunotherapy, screened for and identified the pVAX1-MUC1-VNTR DNA vaccine with the strongest immunogenicity. As a highly malignant carcinoma with the poorest prognosis of all cancers, pancreatic cancer is one of the leading causes of cancer-associated mortality in the USA (2). Therapeutic modalities used to treat pancreatic cancer include chemotherapy, immunotherapy, surgical resection and radiotherapy; however, the survival outcome for patients with pancreatic cancer remains poor (4,6). As a transmembrane mucin glycoprotein that is aberrantly overexpressed in a variety of adenocarcinomas, including pancreatic cancer, MUC1 provides a reliable target for immunotherapy (20). Importantly, the present results demonstrated successful construction of pVAX1-MUC1-VNTR₉, which was shown to enable expression of the target protein in eukaryotic cells. Generally, the peptide backbone of MUC1 is controlled by a region that constitutes 80-200 repetitions of 20-amino-acid repeats (21,22). It is well documented that the MUC1 region, which possesses long branched O-linked carbohydrates, is heavily glycosylated in healthy epithelial cells. By contrast, enhanced expression of MUC1 with heavy glycosylation occurs in unhealthy epithelial cells in the majority of human adenocarcinomas (23). A previous study reported that the majority of pancreatic cancer patients have compromised MUC1-specific immune responses, and are thus unable to inhibit and kill tumor cells (24). The present study presumed that MUC1-VNTR as a new target for immunotherapy, may effectively enhance the immune response to MUC1-positive tumor cells, eliciting and boosting efficacious antigen-specific immune responses.

Another significant finding in the current study was that co-stimulation of immature DCs with the VNTR, antigen and TNF-α was able to robustly induce DC maturation, thereby strongly activating the proliferation of allogeneic T-cells due to the high antigen-presenting ability of mature DCs (25). It has previously been reported that DCs, known as a potent type of antigen-presenting cell, are distributed widely throughout the human body. DCs have been identified in the majority of healthy tissues, and play a crucial role in the immune response to foreign antigens.

**Figure 4.** Effect of pVAX1-MUC1-VNTR DNA vaccine immunization on pANC02-MUC1 tumor growth in mice. The pVAX1-MUC1-VNTR DNA vaccine showed a stronger inhibitory effect on pANC02-MUC1 tumor growth *in vivo* compared with the strong pVAX1-MUC1-VNTR1, VNTR3, VNTR4 and VNTR9 groups. pVAX1-MUC1-VNTR DNA vaccines showed no evident inhibitory effect on pANC02 tumor cells, indicating MUC1 specificity. *P<0.001. MUC1, mucin 1; VNTR, variable number tandem repeat.*

**Figure 5.** Effect of treatment with the pVAX1-MUC1-VNTR DNA vaccines on *in vivo* growth of pANC02-MUC1 tumors. The pVAX1-MUC1-VNTR DNA vaccine showed a stronger inhibitory effect on pANC02-MUC1 tumor growth compared with the strong pVAX1-MUC1-VNTR1, VNTR3, VNTR4 and VNTR9 groups. No evident inhibitory effects on pANC02 tumor cells were observed for all pVAX1-MUC1-VNTR DNA vaccines, indicating MUC1 specificity. *P<0.001. MUC1, mucin 1; VNTR, variable number tandem repeat.*

**Treatment with pVAX1-MUC1-VNTR suppresses pANC02-MUC1 tumor growth in tumor-bearing mice.** The mice were administered subcutaneous injections of pANC02 or pANC02-MUC1 cells and, after 4, 8 and 12 days, received DNA vaccination. As shown in Fig. 5, compared with the empty vector and pANC02 negative groups, growth of pANC02-MUC1 tumors was significantly inhibited from day 9 in the strong pVAX1-MUC1-VNTR1, VNTR3, VNTR4, VNTR9, and VNTR9 groups (all P <0.001). In addition, the suppressive effect of the weak VNTR1 vaccine on pANC02-MUC1 tumor growth was reduced compared with the other p-VAX1-MUC1-VNTR groups (all P<0.05). According to the LSD analysis, the pVAX1-MUC1-VNTR DNA vaccine showed a stronger inhibitory effect on pANC02-MUC1 tumor growth compared with the strong pVAX1-MUC1-VNTR1, VNTR3, VNTR4 and VNTR9 vaccines (all P<0.01), while there was no significant difference among the strong pVAX1-MUC1-VNTR1, VNTR3, VNTR4 and VNTR9 groups (all P>0.05; Fig. 5). No evident inhibitory effects on pANC02 tumor cells were found for all pVAX1-MUC1-VNTR DNA vaccines (Fig. 5), indicating strong MUC1 specificity.
tissues, including the cornea, heart and brain tissues. However, the total quantity of DCs is estimated to be low in the body, only accounting for 1% of peripheral white blood cells and 0.5% of the total number of spleen cells (26). Previous studies have indicated that DCs are capable of activating T lymphocytes, thereby inducing cellular immune responses including CD4+T helper type 1 cells and CD8+T-cells (11,27). In addition, DCs can activate memory B lymphocytes to induce humoral immune responses. Furthermore, DCs are also able to activate natural killer (NK) cells and NKT-cells, which play a unique role in the induction of immune responses (26).

The present study also demonstrated that the amount of IFN-γ-producing CTLs in the MUC1-VNTR group and the MUC1-VNTR group were significantly increased compared with the other groups. In addition, the Lethal effect of CTLs in these two groups on Capan2 cells was significantly stronger compared with the other groups. The extracellular domain, particularly the VNTR region, of MUC1 undergoes marked alterations in posttranslational modifications when normal cells are transformed into tumor cells, and this may lead to variable interactions with the extracellular environment (27). Previous studies in animal models have demonstrated that CTLs alleviate disease severity and promote viral clearance rather than providing sterilizing immunity (28,29). In addition, CTLs induced by DNA vaccination play a key role in eradicating tumors, because the CTLs can directly kill tumor cells and indirectly elicit IFN-γ-mediated antitumor responses (30). The present study adopted DCs transfected with the MUC1-VNTR DNA vaccine as antigen presenting cells to stimulate autologous T lymphocytes and induce the amplification of MUC1-specific CTLs.

The current study determined that the pVAX1-MUC1-VNTR, DNA vaccine had the strongest Lethal effect in both in vivo and in vitro experiments, and demonstrated that this vaccine possessed MUC1 specificity. DNA vaccines are reported to be potentially safer compared with traditional vaccines, in addition to their stability and cost-effectiveness (31). Additionally, the immune system responses activated by anticancer DNA vaccines effectively prevented the occurrence and recurrence of cancer in patients in a previous study (32). A variety of vaccines utilizing MUC1 as the target antigen were shown to induce MUC1-specific humoral and cellular immunity to varying extents, thereby eradicating MUC1-expressing tumor cells (33). Snyder et al (34) indicated that the use of a certain number of tandem repeat sequences in the MUC1-VNTR DNA vaccine was able to induce a robust and strong immune response to target and kill pancreatic cancer cells. In addition, Quinlin et al (35) found that the peptide vaccine, VNTR*, with its PDTRP sequence adjacent to the C-terminus, was characterized by an increased immunogenicity compared with VNTR, with its PDTRP sequence adjacent to the N-terminus. In the present study, protective and therapeutic immune response experiments in mice were performed to further assess the immunogenicity of the DNA vaccines. It was found that the ability of the pVAX1-MUC1-VNTR, DNA vaccine to inhibit panc02-MUC1 tumor growth in vivo was significantly superior to that of the pVAX1-MUC1-VNTR, VNTR, and VNTR DNA vaccines.

In summary, the present study demonstrated that pVAX1-MUC1-VNTR has the potential to express target proteins in eukaryotic cells, and that pVAX1-MUC1-VNTR was characterized by a strong Lethal effect on MUC1-positive tumor cells in both in vivo and in vitro experiments.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (grant nos. 81370059 and 81000917), Guangzhou Science and Technology Research Project (grant no. 2014J4100173) and the Scientific Study Project Foundation of Guangzhou Medical University (grant nos. 2013A43 and 2015C38). The authors would like to acknowledge the reviewers for their helpful comments on this paper.

References

1. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
2. Yadav D and Lowenfels AB: The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144: 1252-1261, 2013.
3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403, 2013.
4. Buanes TA: Pancreatic cancer-improved care achievable. World J Gastroenterol 20: 10405-10418, 2014.
5. Sarkar FH, Banerjee S and Li Y: Pancreatic cancer: Pathogenesis, prevention and treatment. Toxicol Appl Pharmacol 224: 326-336, 2007.
6. Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP and Talamonti MS: Multimodality therapy for pancreatic cancer in the US: Utilization, outcomes, and the effect of hospital volume. Cancer 110: 1227-1234, 2007.
7. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP and Talamonti MS: National failure to operate on early stage pancreatic cancer. Ann Surg 246: 173-180, 2007.
8. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet 378: 607-620, 2011.
9. Uchida Y, Raina D, Kharbanda S and Kufe D: Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. Cancer Biol Ther 14: 127-134, 2013.
10. Grant S: Bortezomib resistance and MUC1 in myeloma. Blood 123: 2910-2912, 2014.
11. Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Yoshimura K, Ueno T, Yoshino S, Sakai K, et al: Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J Transl Med 12: 175, 2014.
12. Kudiyoor A, Schettini J, Besner DM, Rego SL, Nath S, Curry JM, Roy LD, Dréau D and Mukherjee P: Pancreatic cancer cells isolated from Muc1-Null tumors favor the generation of a mature less suppressive MDSC population. Front Immunol 5: 67, 2014.
13. Zhang S, Zhang H, Shi H, Yu X, Kong W and Li W: Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeat sequences. Hum Immunol 69: 250-258, 2008.
14. Wang S, Chen X and Tang M: Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma. Tumour Biol 35: 9101-9109, 2014.
15. Nath S and Mukherjee P: MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 20: 332-342, 2014.
16. Williams JA: Improving DNA vaccine performance through vector design. Curr Gene Ther 14: 170-189, 2014.
17. Weng Y, Shao L, Ouyang H, Liu Y, Yao J, Yang H, Luo Y, Wang H, Zhao Z, Mou H, et al: A unique MUC1-2-VNTR DNA vaccine suppresses tumor growth and prolongs survival in a murine multiple myeloma model. Oncol Rep 27: 1815-1822, 2012.
18. Roulois D, Grégoire M and Fonteneau IF: MUC1-specific cytotoxic T lymphocytes in cancer therapy: Induction and challenge. Biomed Res Int 2013: 871936, 2013.
19. Rong Y, Jin D, Wu W, Lou W, Wang D, Kuang T, Ni X and Qin X: Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 9: 191, 2009.

20. Ueda M, Miura Y, Kunihiro O, Ishikawa T, Ichikawa Y, Endo I, Sekido H, Togo S and Shimada H: MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT). Hepatogastroenterology 52: 398-403, 2005.

21. Engelmann K, Baldus SE and Hanisch FG: Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J Biol Chem 276: 27764-27769, 2001.

22. Baldus SE, Engelmann K and Hanisch FG: MUC1 and the MUCs: A family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41: 189-231, 2004.

23. Hollingsworth MA and Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4: 45-60, 2004.

24. Curry JM, Thompson KI, Rao SG, Besmer DM, Murphy AM, Grdzelishvili VZ, Ahrens WA, McKillop IH, Sindram D, Ianniti DA, et al: The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J Surg Oncol 107: 713-722, 2013.

25. Pei Q, Pan J, Zhu H, Ding X, Liu W, Lv Y, Zou X and Luo H: Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells. Int Immunopharmacol 19: 10-16, 2014.

26. Hon H and Jacob J: Tracking dendritic cells in vivo: Insights into DC biology and function. Immunol Res 29: 69-80, 2004.

27. Zhang L, Vlad A, Milcarek C and Finn OJ: Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62: 423-435, 2013.

28. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, Chan PL, Lam KT, Guan J, Zhang L, et al: Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 84: 6527-6535, 2010.

29. Hillaire ML, Osterhaus AD and Rimmelzwaan GF: Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011: 939860, 2011.

30. Nagata T, Aoshi T, Uchijima M, Suzuki M and Koide Y: Cytotoxic T-lymphocyte-, and helper T-lymphocyte-oriented DNA vaccination. DNA Cell Biol 23: 93-106, 2004.

31. Lu S, Wang S and Grimes-Serrano JM: Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 7: 175-191, 2008.

32. Choi Y, Jeon YH, Jang JY, Chung JK and Kim CW: Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination. Mol Ther 19: 979-989, 2011.

33. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE and Finn OJ: MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6: 18-26, 2013.

34. Snyder LA, Goletz TJ, Gunn GR, Shi FF, Harris MC, Cochlin K, McCauley C, McCarthy SG, Branigan PJ and Knight DM: A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 24: 3340-3352, 2006.

35. Quinlin IS, Burnside JS, Dombrowski KE, Phillips CA, Dolby N and Wright SE: Context of MUC1 epitope: Immunogenicity. Oncol Rep 17: 453-456, 2007.